Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283371 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT03283371 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 67 participants.
The verdict
NCT03283371, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on additional measures of seizure frequency.
Interventions
- OTHER Placebo
- DRUG Natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283371
The ClinicalTrials.gov registry entry for NCT03283371 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03283371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03283371 about?
NCT03283371 is a clinical study titled "Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy". The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab ...
What is the current status of trial NCT03283371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2018-03-20. Estimated completion is 2020-11-18.
What interventions are being tested in trial NCT03283371?
The interventions under investigation include: Placebo (OTHER), Natalizumab (DRUG).
Who is sponsoring clinical trial NCT03283371?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.